Arizona grants nurse practitioners full practice authority. An NP can own the clinic, prescribe, and be their own clinical lead. Here is what that changes, and the four times you still want a physician.
Arizona May Not Require You to Have a Medical Director Read More »
Allstate v. Northfield Medical Center went to the New Jersey Supreme Court in 2017 and produced a four million dollar judgment. The uncomfortable part is who else was held liable.
New Jersey Already Punished the Sham PC. Read the Case. Read More »
Illinois owners budget for the corporate practice of medicine and then get sued over a facial-analysis camera. BIPA is the only statute of its kind in the country, and a med spa is a near-perfect defendant.
Illinois Med Spas Have Two Compliance Problems, and One Is BIPA Read More »
Since 2016 Tennessee has maintained a public online registry of medical spas listing the supervising physician and their license number. That one design choice changes the whole directorship calculus.
Tennessee Publishes Your Medical Director’s Name Read More »
You may never open in Oregon. Read it anyway: Oregon has written down what regulators elsewhere have been circling for a decade, and the drafting is going to be copied.
Oregon SB 951 Is the Strictest MSO Law in the Country Read More »
The FDA signaled movement on BPC-157 and a dozen other peptides, and the market read it as permission. Removal from the do-not-compound list is not the same as approval to compound.
Peptides in 2026: Regulatory Limbo Is Not a Green Light Read More »
Every telehealth TRT clinic prescribes testosterone under a temporary exception with an expiry date. The Ryan Haight in-person requirement was never repealed.
DEA Telemedicine Flexibilities Expire December 31, 2026: What TRT Clinics Must Do Read More »
The FDA approved label changes removing cardiovascular, breast cancer and dementia risk statements from the boxed warning. The endometrial cancer warning stayed, and compounded products were not addressed.
The Hormone Therapy Boxed Warning Is Gone: What Changed and What Didn’t Read More »
Exosome and stem cell products marketed for regeneration are generally regulated as biological drugs, and none is FDA approved for those uses. The claims are usually what triggers enforcement.
Exosomes and Stem Cell Products: Why This Category Draws Enforcement Read More »
The infusion is a routine medical act. The marketing is where clinics get into trouble — reversing aging, repairing DNA, treating addiction. Here is the defensible version.
NAD+ Infusions: What You Can and Cannot Claim Read More »
Blood leaves the patient, is handled, and goes back in through breached skin. The risk is not the product — it is contamination and chain of custody.
PRP and Microneedling: Infection Control Is the Real Risk Read More »
Titrating per label is not microdosing. Deliberately staying sub-therapeutic and advertising it for longevity or metabolic health is a different question entirely.
GLP-1 Microdosing: A Trend Without an Approved Basis Read More »
